Revolutionary Drug Delivery Platform (SDP) that engineers new therapeutics for broader and better clinical outcomes. Our patented lead drug candidate ST-001 nanoFenretinide is a combination of SDP with the cancer drug fenretinide
Location: United States
Total raised: $5.5M
Investors 1
| Date | Name | Website |
| - | City Side ... | citysideve... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 24.09.2025 | - | $5.5M | - |
Mentions in press and media 3
| Date | Title | Description |
| 26.09.2025 | SciTech Development Secures $5.5M, Advances Breakthrough Cancer Therapy | SciTech Development, a clinical-stage oncology firm, successfully raised $5.5 million in funding. This significantly exceeded its initial target, fueling advanced cancer research and development. Its flagship drug, ST-001 nanoFenretinide, s... |
| 24.09.2025 | SciTech Development Raises $5.5M in Funding | SciTech Development, a Detroit, MI-based clinical-stage oncology company, raised $5.5M in funding. Backers were not disclosed. The company intends to use the funds to expand operations and its R&D efforts. Led by CEO Earle Holsapple and... |
| 24.09.2025 | SciTech Development: $5.5 Million Raised For Cancer Clinical Trials Platform | SciTech Development, a clinical-stage oncology company dedicated to pioneering innovative nanotechnology-enabled cancer treatments, is thrilled to announce the successful closure of its third Convertible Note Round, known as CNR 3. This fun... |